Mobile Site ›
Print Friendly View

Test ID: CD20B    
CD20 on B Cells

Secondary ID A test code used for billing and in test definitions created prior to November 2011

89584

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Conditional

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of CD19 deficiency in patients with a suspected CD19 deficiency (humoral immunodeficiency)

 

Confirming complete absence of B cells in suspected primary humoral immunodeficiencies using both CD19 and CD20 markers

 

To assess therapeutic B-cell depletion quantitatively (absolute counts of cells/mcL) in any clinical context, including malignancies, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and membranous glomerulonephritis among others, and treatment or prevention of acute humoral rejection in positive crossmatch renal transplant recipients.

 

This test is not useful for the following applications, instead TAE / Therapeutic Antibody by Flow Cytometry should be ordered in the contexts described below:

-Assessing whether malignant (and nonmalignant) B cells express the target molecule (CD20) of interest in the context of initiating therapeutic monoclonal anti-CD20 antibody therapy (rituximab, ofatumumab, and tositumomab) for any of the hematological malignancies, or in other clinical contexts, such as autoimmunity.

Method Name A short description of the method used to perform the test

Flow Cytometry

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

CD20, B-Cells